Video news


IMBRAVE-151, A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab with or without Bevacizumab in Combination with Cisplatin plus Gemcitabine in Patients with Untreated, Advanced Biliary Tract Cancer


Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab

Show more